Mirvetuximab Soravtansine(IMGN853)——一种靶向叶酸受体α的抗体药物偶联物——在铂耐药卵巢癌、输卵管癌或原发性腹膜癌中的安全性与活性:一项I期扩展研究
该I期扩展队列研究评估了mirvetuximab soravtansine(IMGN853)在叶酸受体α(FRα)阳性且铂耐药的卵巢癌患者中的安全性与临床活性。46例患者接受6.0 mg/kg(调整理想体重)每3周一次给药,确认的客观缓解率为26%,中位无进展生存期(PFS)为4.8个月。在既往治疗线数≤3线的亚组(n=23)中,客观缓解率为39%,PFS为6.7个月。
要点
- 46例铂耐药卵巢癌患者接受IMGN853 6.0 mg/kg每3周一次,最常见治疗相关毒性为腹泻(44%)、视力模糊(41%)、恶心(37%)和乏力(30%)。
- 全部可评估患者的确认客观缓解率为26%,包括1例完全缓解和11例部分缓解,中位PFS为4.8个月,中位缓解持续时间为19.1周。
- 既往治疗线数≤3线的亚组(n=23)客观缓解率为39%,PFS为6.7个月,缓解持续时间为19.6周。
核心结论
- IMGN853表现出可控的安全性特征,在铂耐药卵巢癌中具有活性,在既往治疗较少的个体中观察到最强的疗效信号。
- 基于这些发现,已确定IMGN853单药治疗铂耐药疾病III期试验的剂量、方案和目标人群。
研究设计与样本
- 这是一项I期扩展队列研究,评估mirvetuximab soravtansine(IMGN853)在FRα阳性且铂耐药的卵巢癌患者中的安全性与临床活性。
- 患者为铂耐药上皮性卵巢癌、输卵管癌或原发性腹膜癌,接受IMGN853 6.0 mg/kg(调整理想体重)每3周一次给药。
- 入组条件包括免疫组化FRα阳性最低要求:≥25%的肿瘤细胞染色强度至少为2+。
- 共入组46例患者;评估不良事件、肿瘤缓解(依据RECIST 1.1版)和无进展生存期(PFS)。
主要发现
- 不良事件总体为轻度(≤2级),最常见的治疗相关毒性为腹泻(44%)、视力模糊(41%)、恶心(37%)和乏力(30%)。
- 3级乏力和低血压各报告2例(4%)。
- 全部可评估患者的确认客观缓解率为26%,包括1例完全缓解和11例部分缓解,中位PFS为4.8个月。
- 中位缓解持续时间为19.1周。
- 在既往治疗线数≤3线的亚组(n=23)中,客观缓解率为39%,PFS为6.7个月,缓解持续时间为19.6周。
关键数值与推荐
- FRα阳性免疫组化最低要求:≥25%的肿瘤细胞染色强度至少为2+。
- IMGN853给药剂量为6.0 mg/kg(调整理想体重),每3周一次。
- 全部可评估患者确认客观缓解率为26%,中位PFS为4.8个月,中位缓解持续时间为19.1周。
- 既往治疗线数≤3线亚组(n=23)客观缓解率为39%,PFS为6.7个月,缓解持续时间为19.6周。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose This phase I expansion cohort study evaluated the safety and clinical activity of mirvetuximab soravtansine (IMGN853), an antibody-drug conjugate consisting of a humanized anti-folate receptor alpha (FRα) monoclonal antibody linked to the tubulin-disrupting maytansinoid DM4, in a population of patients with FRα-positive and platinum-resistant ovarian cancer. Patients and Methods Patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer received IMGN853 at 6.0 mg/kg (adjusted ideal body weight) once every 3 weeks. Eligibility included a minimum requirement of FRα positivity by immunohistochemistry (≥ 25% of tumor cells with at least 2+ staining intensity). Adverse events, tumor response (via Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1), and progression-free survival (PFS) were determined. Results Forty-six patients were enrolled. Adverse events were generally mild (≤ grade 2), with diarrhea (44%), blurred vision (41%), nausea (37%), and fatigue (30%) being the most commonly observed treatment-related toxicities. Grade 3 fatigue and hypotension were reported in two patients each (4%). For all evaluable patients, the confirmed objective response rate was 26%, including one complete and 11 partial responses, and the median PFS was 4.8 months. The median duration of response was 19.1 weeks. Notably, in the subset of patients who had received three or fewer prior lines of therapy (n = 23), an objective response rate of 39%, PFS of 6.7 months, and duration of response of 19.6 weeks were observed. Conclusion IMGN853 exhibited a manageable safety profile and was active in platinum-resistant ovarian cancer, with the strongest signals of efficacy observed in less heavily pretreated individuals. On the basis of these findings, the dose, schedule, and target population were identified for a phase III trial of IMGN853 monotherapy in patients with platinum-resistant disease.
引用
- Moore KN, Martin LP, O'Malley DM, et al. Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. J Clin Oncol. 2016. PMID: 28029313. doi:10.1200/JCO.2016.69.9538
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。